Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bentley Pharmaceuticals has entered into a licensing agreement with Dong Sung Pharm Co Ltd for the development of an intranasal spray formulation of insulin for the South Korean market and possibly additional territories.
Subscribe to our email newsletter
The agreement is Bentley’s first to develop and license its intranasal spray formulation of insulin. Under the agreement, the two companies have agreed to conduct phase II and phase III studies designed to comply with international standards applicable for regulatory submissions in South Korea and possibly in other countries.
A joint working team consisting of Bentley and Dong Sung employees, as well as consultants, will guide the development process in Korea. Dong Sung will fund the appropriate studies and submit the regulatory documents required for their licensed territory. Bentley will provide clinical and commercial supplies of insulin formulations, as well as metered administration devices.
“We are very pleased to sign our first agreement for developing and licensing our intranasal delivery of insulin,” commented James Murphy, chairman and CEO of Bentley. “The generation of more advanced clinical data through this collaboration could be very valuable in assisting and supporting our other developmental strategies for Asia, the EU and the US.”
Bentley previously announced that it will report the results of its initial phase II clinical trial in an abstract at the American Diabetes Association 65th Scientific Sessions in California in June.